1.2K(top 12%)
articles
79.9K(top 6%)
citations
614(top 7%)
★★ articles
8(top 10%)
★★★ articles
3.2(top 11%)
Avg IF
140(top 4%)
H-Index
258(top 4%)
G-Index
195
journals

Most Cited Articles of American Society of Clinical Oncology in 2006

TitleJournalYearCitations
2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJournal of Clinical Oncology20061.4K
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancerJournal of Clinical Oncology20061.1K
American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006Journal of Clinical Oncology2006610
American Society of Clinical Oncology clinical practice guideline for the use of larynx-preservation strategies in the treatment of laryngeal cancerJournal of Clinical Oncology2006358
Radiation therapy for hepatocellular carcinoma: from palliation to cureCancer2006196
Mayo clinic consensus statement for the use of bisphosphonates in multiple myelomaMayo Clinic Proceedings2006193
AIDS-related non-Hodgkin lymphoma: final analysis of 485 patients treated with risk-adapted intensive chemotherapyBlood2006114
Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical OncologyJournal of Clinical Oncology200695
Reimbursement for cancer treatment: coverage of off-label drug indicationsJournal of Clinical Oncology200663
Phase II study of fixed dose rate gemcitabine with cisplatin for metastatic adenocarcinoma of the pancreasJournal of Clinical Oncology200663
A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008Cancer200660
Vinorelbine plus trastuzumab combination as first-line therapy for HER 2-positive metastatic breast cancer patients: an international phase II trialBritish Journal of Cancer200650
ASCO-ESMO consensus statement on quality cancer careAnnals of Oncology200631
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumorsCancer Chemotherapy and Pharmacology20065
Introduction: ASCO-ESMO consensus statement on quality cancer careAnnals of Oncology20065
Cancer biology and implications for practiceClinical Journal of Oncology Nursing20064
Bcr-Abl Kinase InhibitorsTopics in Medicinal Chemistry20064
Evaluating end of life care: The Quality Oncology Practice Initiative (QOPI) experienceJournal of Clinical Oncology20063
Introduction: ASCO-ESMO Consensus Statement on Quality Cancer CareJournal of Clinical Oncology20061
We have a new treatment, but you can't afford itJournal of the National Comprehensive Cancer Network: JNCCN2006